CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

ONCOLOGY. Vol. 23 No. 3
Pages: 1  2  3  4  5  
Previous Next
NCI WORKSHOP 

Current Status and Future Potential of Advanced Technologies in Radiation Oncology

Part 1. Challenges and Resources

By BHADRASAIN VIKRAM, MD
Chief
Clinical Radiation Oncology Branch

 

C. NORMAN COLEMAN, MD
Associate Director
Radiation Research Program

 

JAMES A. DEYE, PhD
Program Director
Medical Physics
Radiation Research Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Rockville, Maryland
| March 16, 2009

Financial Disclosure: The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

Disclaimer: The opinions and conclusions in this report are those of the individual authors and participants and do not reflect an opinion or policy of the National Cancer Institute or the US Government.


IMRT Guidelines
In 2004, the NCI first established guidelines for the writing of and participation in NCI-supported cooperative group protocols that employ IMRT. Those guidelines were updated in 2006, and are available at http://atc. wustl.edu/home/NCI/NCI_IMRT_ Guidelines.html. Each institution participating in such an NCI-supported protocol must be credentialed by the group (eg, RTOG, Children’s Oncology Group [COG]) in charge of the protocol.

Proton Radiation Therapy Guidelines
In 2007, the NCI established guidelines for the writing of and participation in protocols that employed protons. Those guidelines are available at http://www.qarc.org/benchmarks/ ProtonGuidelines_June2007.pdf. Each institution participating in such an NCI-supported protocol must be credentialed by the group (eg, RTOG, COG) in charge of the protocol.

Advanced Technology Consortium
The Advanced Technology Consortium (ATC), whose website can be found at http://atc.wustl.edu/, supports the development and execution of, and digital data exchange for, a growing number of clinical trials (both NCI-funded and others) that utilize the advanced technologies. The consortium has devised a methodology for decreasing interinstitutional variations in the key step of submitting information used for verifying the use of registration (fusion) software for combining different kinds of images. It is currently working on a solution to the problem that some treatment planning systems have when calculating doses in the presence of tissue heterogeneities. It is also designing phantoms to simulate target motion due to respiration.[9]

The ATC seeks to create an environment in which clinical investigators can receive, share, and analyze volumetric, multimodality treatment planning and verification digital data, thereby improving the quality of clinical trials involving advanced technology radiation therapy. The quality assurance requirements change as the technology evolves, and also from protocol to protocol depending upon the question(s) being addressed. The ATC develops uniform processes and an infrastructure to assist the cooperative groups in assuring quality, but the actual responsibility for quality assurance belongs to the investigators and cooperative group(s) conducting the trial.

Patient-Reported Outcomes Measurement Information System
Much of the impact of the advanced technologies in radiation oncology, at least in the short-term, will likely be to decrease toxicity by decreasing the volume of nonmalignant tissues subjected to high doses of radiation while treating common cancers. In other words, these technologies may help patients live better (with a better quality of life) rather than longer. Measuring the quality of life can be challenging, however, and many researchers in radiation oncology are not well versed in that methodology.

Pages: 1  2  3  4  5  
Previous Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
CME ACTIVITIES

Current Challenges in Metastatic Breast Cancer:

Patient Management and Treatment Strategies

Interactive Case Challenge Series

 

This series of case presentations (five individual cases) will provide oncologists and other healthcare professionals with strategies for evaluating evidence-based data on the latest treatments in metastatic breast cancer (MBC) and the application of that data into the development of individualized approaches to care, including overcoming resistance, in order to optimize management and outcomes for patients.

 

Go to Activity

 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Join us on
LinkedIn
Sign up for our
Newsletters
Subscribe to our
RSS Feed
CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy